Tel Aviv, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, today announced that on August 12, 2025, Fort Technology Inc. (“Fort”) (TSXV: FORT), a company listed on the TSX Venture Exchange, in which Jeffs’ Brands holds a 75.02% equity stake, has entered into a private placement of convertible debentures (the “Convertible Debentures”) for gross proceeds of up to CAD 5 mil ...

Defines Drill TargetsVANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Latin Metals Inc. ("Latin Metals" or the "Company") - (TSXV: LMS) (OTCQB: LMSQF) is pleased to announce that its 100% owned subsidiary Zafiro Mining S.A.C. has acquired additional mineral rights contiguous to the Para copper project ("Para" or the "Project") in southern Peru. This acquisition expands the Project to the south and secures coverage over key drill targets (Figures 1 and 2). Key Takeaways: New Land Secured: Strat ...

ROCHESTER, NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Syntec Optics Holdings, Inc. (Nasdaq: OPTX) (“Syntec Optics” or the “Company”), a leading provider of technology products to defense, biomedical, communications, and consumer industry leaders, today highlighted its critical role in enabling the next generation of advanced hyperspectral imaging (HSI) technology. The company manufactures the core elements that power state-of-the-art HSI systems used in defense markets. Hyperspectral imaging is a powerful ...

ATHENS, Greece, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Euroseas Ltd. (NASDAQ: ESEA, the “Company” or “Euroseas”), an owner and operator of container carrier vessels and provider of seaborne transportation for containerized cargoes, announced today its results for the three- and six-month periods ended June 30, 2025. Second Quarter 2025 Financial Highlights: Total net revenues of $57.2 million. Net income of $29.9 million or $4.32 and $4.29 earnings per share basic and diluted, respectively. Adjusted net income1 ...

San Diego, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- HUMBL, Inc. (OTC: HMBL) is proud to announce that it will begin selling the CortexPC – a proprietary line of AI-native computers. The CortexPC will be powered by the MultiCortex operating system, a revolutionary platform designed for next-generation personal and enterprise computing, with a full focus on privacy and high performance. This launch delivers computers with an AI-native operating system and heterogeneous computing capabilities. The solution addres ...

Core Viewpoint - Scienture Holdings, Inc. has announced the shipment of launch quantities of Arbli (losartan potassium) Oral Suspension, marking a significant milestone for the company as it prepares for the commercial launch of this novel product aimed at treating hypertension and related conditions [1][5]. Product Overview - Arbli is the first and only FDA-approved ready-to-use oral liquid formulation of losartan in the U.S. market, designed for patients over 6 years old [2][6]. - The product is indicated for the treatment of hypertension, reduction of stroke risk in patients with hypertension and left ventricular hypertrophy, and treatment of diabetic nephropathy in certain type 2 diabetes patients [8][10]. - Arbli offers a tailored approach for patients who require or prefer a liquid option, ensuring easier and safer dosing without the need for compounding [3][4]. Market Context - Losartan is classified as an angiotensin receptor blocker (ARB) and is one of the most prescribed medications for hypertension, with total annual sales of approximately $276 million and a prescription volume of 69 million in the U.S. as of March 2025 [4]. - The global market for losartan potassium was valued at approximately $1.5 billion in sales in 2024 [4]. Company Strategy - The shipment of Arbli to the distribution center and the receipt of the first order are seen as critical milestones in Scienture's efforts to deliver the product to healthcare providers [5]. - The company emphasizes its commitment to quality by ensuring compliance with Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP) standards [5]. Product Specifications - Arbli is available in a 165 mL bottle as a peppermint-flavored suspension that does not require refrigeration and has a shelf life of 24 months when stored at room temperature [6].

Core Insights - Moleculin Biotech, Inc. is making significant progress in its Phase 2B/3 MIRACLE trial for Annamycin, targeting relapsed or refractory acute myeloid leukemia (AML) with an expected data readout before the end of 2025 [1][2][21] Clinical Development Updates - The MIRACLE trial is expanding with over 20 additional clinical sites expected to begin recruitment by the end of Q3 2025, including locations in the US, Europe, and the Middle East [1][7] - The trial utilizes an adaptive design, with the first 75 to 90 subjects randomized to receive different doses of Annamycin combined with high-dose cytarabine [6][10] - Preliminary efficacy data is expected to be unblinded for the first 45 subjects treated before the end of 2025, with a second unblinding anticipated in the first half of 2026 [8] Financial Results - For Q2 2025, the company reported a research and development expense of $3.6 million, down from $4.1 million in Q2 2024, primarily due to reduced clinical trial activity [18] - General and administrative expenses remained stable at $2.1 million for both Q2 2025 and Q2 2024 [18] - As of June 30, 2025, the company had cash and cash equivalents of $7.6 million, which is expected to fund operations into Q4 2025 [19] Annamycin Development Milestones - Annamycin has received Fast Track Status and Orphan Drug Designation from the FDA for the treatment of relapsed or refractory AML and soft tissue sarcoma [15] - Positive topline results from the U.S. Phase 1B/2 trial for Annamycin in treating soft tissue sarcoma lung metastases showed a median overall survival of 13.5 months, compared to 8-12 months for standard treatments [13] Intellectual Property and Strategic Partnerships - The company has bolstered its intellectual property portfolio with a notice of intent to grant a new European patent for Annamycin [7] - An industry veteran has been engaged to explore strategic partnerships related to Annamycin [7]

Core Viewpoint - Worksport Ltd. reaffirms its revenue target of at least $20 million for 2025 and highlights a clear path towards achieving operational cash flow positivity in the near term [1][6]. Financial Performance - In Q2 2025, Worksport achieved record net sales of $4.10 million, representing a 114% increase year-over-year and an 83% increase sequentially [2]. - Gross margin improved by 8.7 percentage points to 26.4%, leading to a 173% increase in gross profit to $1.08 million [2]. - Operating loss decreased by 15% quarter-over-quarter to $(3.62) million, while net loss narrowed by approximately 16% to $(3.73) million [2][6]. - Operating cash use improved by 19% to $(3.10) million, with total liquidity at approximately $6.1 million [2][6]. Sales and Dealer Network - The company set three consecutive monthly sales records in Q2, with April at $1.22 million, May at $1.28 million, and June at $1.60 million, leading to an annualized run rate of $19.2 million [3]. - Year-to-date, Worksport has added over 450 new dealer accounts, with a network capable of generating approximately $21.5 million in annual repeatable revenue [3]. Operational Highlights - Q3 2025 output is expected to be significantly stronger than Q2, with July output averaging 115-130 units per day and targeting ~200 units per day by late Q3 [8]. - The innovation pipeline includes the upcoming launches of HD3, SOLIS, and COR products, with SOLIS and COR expected to contribute to revenue in 2026 [8][9]. Management Commentary - CEO Steven Rossi emphasized that the company is executing towards operational cash-flow positivity and preparing for product launches, believing that the tonneau business alone can lead to profitability in 2026 [5]. - CFO Michael Johnston highlighted strong sequential leverage, with expectations for gross margin to approach 30% by year-end and targeting operating cash-flow breakeven by late Q4 2025 or early Q1 2026 [6]. Capital and Liquidity - The company expects to close its current Regulation A offering by the end of August 2025, which, if fully subscribed at $10 million, would provide funding through 2025 and into 2026 [13]. - Outstanding warrants may provide growth capital in 2026, with the company aiming to limit notable equity dilution while pursuing disciplined growth [13].

BERKELEY, Calif. and MAINZ, Germany, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces today that ColoAlert®, its non-invasive colorectal cancer (CRC) screening test, has been officially registered and approved for distribution by Swissmedic, the Swiss regulatory and supervisory authority for medicinal products and medical devices. In Switzerland, CRC screening ...

TORONTO, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Altus Group Limited (ʺAltus Group” or “the Company”) (TSX: AIF) issued a statement in response to recent media reports concerning a potential transaction involving the Company. While the Company has a policy not to comment on market rumours, it acknowledges a speculative recent media article. Altus Group periodically undertakes a strategic review to maximize stakeholder value. The Company is in the process of a review which includes but is not limited to acquisitio ...